KOSDAQBiotech & Pharma348150

KoBioLabs

₩2,565▲ 0.39%2026-11-18 close
Market Cap
₩49.8B
Turnover
₩9,251,255
Volume
3.6K
Shares out.
19.4M
PER
—
PBR
1.9×
EPS
-₩327
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Licensing deal yet losses persist at KoBioLabs

A KRW 205.2 billion licensing deal with Celltrion has shifted the business toward partnered clinical development, yet filed results show losses in each of the last five quarters through Q3 2026.

  1. 1

    The business is built around licensing. The total value of the Celltrion agreement is KRW 205.2 billion, but the upfront payment is KRW 1 billion and the rest depends on clinical, approval and sales milestones.

  2. 2

    Revenue rose for three consecutive years from 2023 to 2025, reaching KRW 69.3 billion in 2025. Q3 2026 revenue was KRW 20.4 billion, up 6.2% year on year.

  3. 3

    The operating loss widened to KRW 0.965 billion in 2025. The Q3 2026 operating loss of KRW 3.16 billion was a wider loss than the KRW 0.42 billion operating loss in the year-earlier quarter.

  4. 4

    Net income attributable to controlling shareholders turned positive in Q1 2026, then returned to losses of KRW 3.8 billion in Q2 and KRW 1.43 billion in Q3.

  5. 5

    Operating cash flow was negative every year from 2022 to 2025, and the debt-to-equity ratio rose from 29.8% in 2022 to 85.2% in 2025.

02

Business structure

KoBioLabs is a microbiome-based drug developer founded in 2014 and listed on KOSDAQ in 2020. The company emphasizes an early-monetization model, securing pipeline value at the preclinical or early clinical stage and then monetizing it through joint research and licensing.

Its main transaction is the Celltrion licensing deal disclosed on March 25, 2026, which transferred worldwide exclusive rights to candidates KC84, KBL382 and KBL385, with a total value of KRW 205.2 billion.

The KRW 1 billion upfront payment was received in Q2, and the remainder is structured as development milestones of KRW 7.2 billion, approval milestones of KRW 13 billion and sales milestones of KRW 184 billion, paid in stages. Royalties on net sales after commercialization are paid separately.

The company's own pipeline has been quiet on large trials since it voluntarily withdrew the Phase 2a study of its ulcerative colitis candidate KBL697 in July 2023.

Its health-food business sits in subsidiary Wibiome, a joint venture formed with E-Mart in 2022, which is driving sales through home shopping and online channels and is expanding into probiotic ingredient supply.

The mDDS drug-delivery platform, based on synthetic biology, is positioned as the next growth engine, and the company discussed joint research and licensing with global pharma companies at BIO-Europe 2026 from November 9 to 11.

Among KOSDAQ-listed microbiome companies, KoBioLabs is one of the few still pursuing drug development, and its research staff rose from 32 at the 2020 listing to 48 in 2025. Ko Kwang-pyo and 10 related parties hold 29.99%.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩19.3B-₩400M−2.2%
2025Q4₩15.1B-₩3B−19.6%
2026Q1₩19.2B-₩2.7B−13.9%
2026Q2₩21.8B-₩2B−9.2%
2026Q3₩20.4B-₩3.2B−15.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩11.6B-₩20.3B-₩21.9B−174.8%−28.4%29.8%
2023₩33.1B-₩18.5B-₩13.9B−55.7%−30.8%85.4%
2024₩68.4B-₩6.9B-₩5.3B−10.1%−14.0%84.0%
2025₩69.3B-₩9.7B-₩6.3B−13.9%−19.5%85.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual results show revenue growth alongside continued losses. Revenue rose from KRW 11.6 billion in 2022 to KRW 33.1 billion in 2023 (up 185.5% year on year) and KRW 68.4 billion in 2024 (up 106.3%), then grew only 1.4% to KRW 69.3 billion in 2025.

Revenue increased for three consecutive years from 2023 through 2025, and 2025 was the largest year of 2022 to 2025. Operating loss narrowed from KRW 20.3 billion in 2022 to KRW 18.5 billion in 2023 and KRW 6.91 billion in 2024, then widened to KRW 9.65 billion in 2025.

The operating margin improved from -174.8% in 2022 to -10.1% in 2024 before slipping to -13.9% in 2025. Net loss attributable to controlling shareholders was KRW 21.9 billion in 2022, KRW 13.9 billion in 2023, KRW 5.3 billion in 2024 and KRW 6.33 billion in 2025.

Consolidated net loss including non-controlling interests, a different figure, was KRW 23.4 billion in 2022 and KRW 6.97 billion in 2025. Operating cash flow was negative in every year, at KRW -16.6 billion in 2022, KRW -13.8 billion in 2023, KRW -4.36 billion in 2024 and KRW -5.78 billion in 2025.

The debt-to-equity ratio jumped from 29.8% in 2022 to 85.4% in 2023 and was 85.2% in 2025. At year-end 2025, total equity was KRW 49.3 billion, of which KRW 32.4 billion belonged to controlling shareholders, and total liabilities were KRW 42 billion.

Quarterly revenue fell 21.5% quarter on quarter to KRW 15.1 billion in Q4 2025 before recovering to KRW 19.2 billion in Q1 2026 and KRW 21.8 billion in Q2 2026, then reached KRW 20.4 billion in Q3 2026, up 6.2% year on year.

Operating loss widened from KRW 423 million in Q3 2025 to KRW 2.96 billion in Q4 2025, narrowed to KRW 2.67 billion in Q1 2026 and KRW 2.01 billion in Q2 2026, then widened again to KRW 3.16 billion in Q3 2026.

Net income attributable to controlling shareholders turned positive at KRW 1.13 million in Q1 2026, then returned to losses of KRW 3.8 billion in Q2 and KRW 1.43 billion in Q3. The four quarters from Q4 2025 through Q3 2026 total a controlling-shareholder net loss of KRW 6.36 billion.

The KRW 1 billion upfront payment from Celltrion was received in Q2 2026 and is a one-time item, with the timing of later milestone recognition still unset.

Separately, a news report on the 2026 half-year report said first-half consolidated revenue rose 17.5% to KRW 41.0 billion and operating loss narrowed 25.3% to KRW 4.68 billion (disclosed August 13, 2026).

05

Industry analysis

Microbiome drugs drew heavy attention in Korean equities in the early 2020s, but commercial results from FDA-approved microbiome therapies and clinical outcomes at domestic and overseas developers fell short of expectations, pulling investor interest away.

Some companies narrowed their technology to areas such as cosmetics or shifted to other modalities such as antibodies. In this environment KoBioLabs is among the few listed companies still pursuing microbiome drug development.

Reports say its R&D spending as a share of revenue has been declining as health-food sales grew, and the absence of large-scale clinical trials since 2023 is cited as the background.

Licensing activity overall is active: on March 25, 2026, Alteogen announced a KRW 867.5 billion ALT-B4 technology export deal with Switzerland's Biogen.

Celltrion holds clear leadership in gut-disease treatment through Remsima and Steqeyma and is now the partner handling global clinical development and commercialization of KoBioLabs' candidates. The licensed candidates cover all gut-disease indications, including IBS-d.

Because microbiome drugs use live microorganisms, proof of concept is considered one of the highest hurdles in the field. Whether Celltrion secures PoC quickly through early-stage efficacy testing will be a key variable for the sector.

On the platform side, the synthetic-biology-based mDDS system is presented as a way to address systemic toxicity and short half-life of anticancer drugs, and the company is currently in discussions with global pharma companies on joint research and licensing.

06

Outlook

The company's stated direction is to secure value at the preclinical or early clinical stage and convert it into joint research and licensing. The most important checkpoint is how the Celltrion deal is recognized as revenue.

The KRW 1 billion upfront payment was received in Q2, and the development milestones of KRW 7.2 billion, approval milestones of KRW 13 billion and sales milestones of KRW 184 billion come in stages as conditions are met.

Reports also say up to USD 104.75 million in additional clinical, approval and commercial milestones is possible. Celltrion has said it will focus on efficacy verification from the early clinical stage to secure PoC quickly. The company plans to use the proceeds to accelerate development of follow-on pipeline assets.

The two companies previously ran joint research on IBS-d and atopic dermatitis and said they will review further commercialization possibilities. The company plans to pursue partnerships with suitable partners by the end of Phase 2.

On the platform side, it presented mDDS research status to global pharma companies at BIO-Europe 2026 from November 9 to 11 and discussed joint research and licensing.

In Korea, the company joined a national AI healthcare project led by Kakao Healthcare from 2026 and plans to develop a pediatric allergy diagnosis and prediction model combining microbiome data with AI.

Its subsidiary Wibiome is expanding the supply of probiotic ingredients based on patented strains to global customers. The next checkpoints are the operating profit and operating cash flow in the 2026 annual report, and whether milestone recognition from the Celltrion deal begins.

07

Valuation

PER
—
PBR
1.9×
ROE
-21.3%
EPS
-₩327
BPS
₩1,388
Dividend per share
₩0

The price-to-book ratio is above 1x, which means the stock trades at a premium to net assets. The denominator is book value based on KRW 32.4 billion of equity attributable to controlling shareholders at year-end 2025, out of total equity of KRW 49.3 billion.

Because net losses attributable to controlling shareholders continued over the most recent four quarters, the price-to-earnings ratio is not calculated. The dividend yield is below the industry average.

On earnings, the company turned profitable in Q1 2026, but later quarters returned to losses, which limits earnings-based multiple comparisons.

On enterprise value, the KRW 205.2 billion licensing deal is a sum of staged milestones, and revenue beyond the KRW 1 billion upfront payment depends on clinical, approval and sales progress.

The key interpretive question for the current price is therefore how much expectation for pipeline progress is already reflected.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Large milestone-based licensing deal

The total value of the Celltrion deal is KRW 205.2 billion, more than four times total equity of KRW 49.3 billion at year-end 2025. Beyond the KRW 1 billion upfront payment, revenue builds with clinical progress and approval and sales stages, so achieving each step becomes the axis of earnings improvement. Royalties on net sales after commercialization are paid separately.

Revenue recovery and subsidiary growth

Quarterly revenue fell to KRW 15.1 billion in Q4 2025, then recovered to KRW 19.2 billion in Q1 2026 and KRW 21.8 billion in Q2 2026. Health-food sales at subsidiary Wibiome are cited as driving growth through home shopping and online channels.

Narrowing losses history and platform expansion

Operating loss narrowed from KRW 20.3 billion in 2022 to KRW 6.91 billion in 2024, and the operating margin improved from -174.8% to -10.1% over the same period. Net income attributable to controlling shareholders turned positive in Q1 2026. The synthetic-biology mDDS platform has moved into discussions with global pharma companies.

09

Bear factors

Persistent losses and wider recent losses

Operating losses and net losses attributable to controlling shareholders continued from 2022 through 2025. The Q3 2026 operating loss of KRW 3.16 billion widened from KRW 423 million a year earlier.

The four quarters from Q4 2025 through Q3 2026 total a controlling-shareholder net loss of KRW 6.36 billion, and quarterly swings are large, as the KRW 3.8 billion Q2 2026 loss shows.

Operating cash outflows and higher leverage

Operating cash flow was negative every year, from KRW -16.6 billion in 2022 to KRW -5.78 billion in 2025. The debt-to-equity ratio jumped from 29.8% in 2022 to 85.4% in 2023 and was 85.2% in 2025. Of total equity of KRW 49.3 billion at year-end 2025, KRW 32.4 billion belonged to controlling shareholders.

Timing uncertainty of milestone income

Apart from the KRW 1 billion upfront payment, most of the Celltrion revenue is tied to milestones linked to clinical progress and commercialization. One report said timing and scale of income carry volatility and that short-term earnings improvement will take time. Clinical efficacy and market credibility for microbiome therapies are also flagged as challenges.

10

Risk factors

Clinical development risk

The company voluntarily withdrew the Phase 2a study of KBL697 in July 2023. Candidates licensed to Celltrion still need efficacy verification after entering clinical testing, and because microbiome drugs use live organisms, PoC is seen as one of the highest hurdles. If pipeline progress stalls, milestone income could be delayed or never received.

Earnings structure and cash flow

The operating margin was -13.9% in 2025, and operating cash flow was negative in every year from 2022 to 2025. Apart from the upfront payment, licensing income arrives as milestones are met, so quarterly results are volatile. The Q3 2026 operating loss also widened from a year earlier.

Governance and shareholder concentration

At the March 26, 2026 annual shareholder meeting, Lee Han-seung was appointed CEO and founder Ko Kwang-pyo moved to Chief Vision Officer. Ko Kwang-pyo and 10 related parties hold 29.99%, a concentrated shareholder base. Whether the new management structure delivers on its strategy remains to be seen.

11

What to watch next

  1. Late March 2027

    Deadline for the 2026 annual report. It is the checkpoint for full-year revenue, operating profit and loss, operating cash flow, and whether Celltrion upfront and milestone income is recognized.

  2. Around March 2027 (based on 2026 meeting timing)

    Expected timing of the annual shareholder meeting, based on the March 26, 2026 meeting. It is the checkpoint for board composition and shareholder-approved items such as business purpose changes.

  3. May 15, 2027

    Deadline for the Q1 2027 quarterly report, 45 days after quarter end. It is the checkpoint for comparing Q1 2027 revenue and operating result with KRW 19.2 billion of revenue and KRW 2.67 billion of operating loss in Q1 2026.

  4. Timing not yet announced

    Whether Celltrion secures early clinical PoC data on candidates such as KC84. Any disclosed clinical progress would serve as an indicator of the likelihood of milestone achievement.

12

Overall view

KoBioLabs has shifted its business toward an early-licensing model with a KRW 205.2 billion Celltrion deal. Revenue rose for three consecutive years from 2023 to 2025, reaching KRW 69.3 billion in 2025, and Q3 2026 revenue of KRW 20.4 billion was up 6.2% year on year.

On the other hand, the operating loss widened to KRW 9.65 billion in 2025, and Q3 2026 still recorded an operating loss of KRW 3.16 billion.

Net income attributable to controlling shareholders turned positive in Q1 2026 but returned to losses in Q2 and Q3, with a four-quarter total controlling-shareholder net loss of KRW 6.36 billion.

Operating cash flow has been negative every year since 2022, and the debt-to-equity ratio was 85.2% in 2025, up from 29.8% in 2022. Most of the large contract value consists of clinical, approval and sales milestones, so the timing of income is uncertain, and that uncertainty supports both the bull and bear cases.

The next checkpoints are the operating profit and cash flow in the 2026 annual report and whether Celltrion milestone income begins to be recognized.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. comp.wisereport.co.kr
  2. mt.co.kr
  3. thevc.kr
  4. infostockdaily.co.kr
  5. m.news.nate.com
  6. medipana.com
  7. biobookmedia.com
  8. m.news.nate.com
  9. msn.com
  10. v.daum.net
  11. news.nate.com
  12. newspim.com
  13. news.nate.com
  14. thebionews.net
  15. edaily.co.kr
  16. newspim.com
  17. hitnews.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis